Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 20/20 | 1.00 |
| ▸ | PSEN2 | P49810 | 20/20 | 1.00 |
| ▸ | APH1B | Q8WW43 | 20/20 | 1.00 |
| ▸ | NCSTN | Q92542 | 20/20 | 1.00 |
| ▸ | APH1A | Q96BI3 | 20/20 | 1.00 |
| ▸ | PSENEN | Q9NZ42 | 20/20 | 1.00 |
| ▸ | SPPL2A | Q8TCT8 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30957093 | 1.00 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL20495533 | 1.00 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL29358197 | 1.00 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL12525071 | 1.00 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL13749875 | 1.00 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL23855805 | 1.00 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL29666504 | 1.00 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5620296 | 0.92 | PSEN1 (0.85) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4419147 | 0.89 | PSEN1 (0.80) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL18425107 | 0.84 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9572815-B2 | Methods and compositions of p27KIP1 transcriptional modulators | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2017-02-21 | — | — | US | claimed |
| US-12318391-B2 | Methods and compositions for the prevention and treatment of hearing loss | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. | 2025-06-03 | — | — | US | disclosed |
| CN-119679936-A | Dosing regimen and combination therapy for multispecific antibodies directed against B cell maturation antigens | 诺华股份有限公司 | 2025-03-25 | — | — | CN | disclosed |
| US-12161647-B2 | Treating hearing loss | MASSACHUSETTS EYE & EAR INFIRMARY (US) | 2024-12-10 | — | — | US | disclosed |
| CN-118994397-A | Trispecific binding molecules directed against BCMA and uses thereof | 诺华股份有限公司 | 2024-11-22 | — | — | CN | disclosed |
| CN-114173810-B | Trispecific binding molecules directed against BCMA and uses thereof | 诺华股份有限公司 | 2024-09-06 | — | — | CN | disclosed |
| EP-3786164-B1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF HEARING LOSS | TING THERAPEUTICS LLC (US) | 2024-08-14 | — | — | EP | disclosed |
| CN-118459594-A | Binding molecules to BCMA and uses thereof | 诺华股份有限公司 | 2024-08-09 | — | — | CN | disclosed |
| US-12043653-B2 | Efficient delivery of therapeutic molecules to cells of the inner ear | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2024-07-23 | — | — | US | disclosed |
| WO-2024113354-A1 | CULTURE MEDIUM, COATING MATRIX AND METHOD FOR EXPANDING MIDBRAIN DOPAMINERGIC PROGENITOR CELLS | NUWACELL BIOTECHNOLOGIES CO., LTD. (CN) | 2024-06-06 | — | — | WO | disclosed |
| WO-2008027345-A2 | COMBINED γ-SECRETASE INHIBITOR AND PHENOTHIAZINE DERIVATIVE TREATMENT OF NEURODEGENERATIVE DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-03-06 | — | — | WO | disclosed |
| US-20080045499-A1 | Preferential Inhibition of Presenilin-1 | ELAN PHARMACEUTICALS, INC. | 2008-02-21 | — | — | US | disclosed |
| US-20080045499-A1 | Preferential Inhibition of Presenilin-1 | ELAN PHARMACEUTICALS, INC. | 2008-02-21 | — | — | US | disclosed |
| US-20070219181-A1 | Multi-cyclic cinnamide derivatives | EISAI R&D MANAGEMENT CO., LTD. | 2007-09-20 | — | — | US | disclosed |
| US-20070190046-A1 | Anti-abeta antibody | ELI LILLY AND COMPANY | 2007-08-16 | — | — | US | disclosed |
| US-20070190046-A1 | Anti-abeta antibody | ELI LILLY AND COMPANY | 2007-08-16 | — | — | US | disclosed |
| US-20070117839-A1 | Two cyclic cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. | 2007-05-24 | — | — | US | disclosed |
| US-20070117798-A1 | Morpholine type cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. | 2007-05-24 | — | — | US | disclosed |
| EP-1757591-A1 | CINNAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2007-02-28 | — | — | EP | disclosed |
| US-20060004013-A1 | Alzheimer's disease, senile dementia, Down syndrome or amyloidosis; 3E)-1-[(1S)-1-(4-fluorophenyl)ethyl]-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]piperidin-2-one; imidazolyl-functional compounds inhibit production of Amyloid beta 40 and Amyloid beta 42; low hygroscopicity; good solubility | EISAI CO., LTD. | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12318391-B2 | Methods and compositions for the prevention and treatment of hearing loss | CDK2, CDK5, CDK20 | PSEN1 327/4885PSEN2 135/4885APH1B 588/4885 |
| US-20070117798-A1 | Morpholine type cinnamide compound | MLX, XDH, NOX4 | PSEN1 3103/4885PSEN2 4126/4885APH1B 4110/4885 |
| US-12161647-B2 | Treating hearing loss | BACE1, BACE2, PSENEN | PSEN1 9/4885PSEN2 10/4885APH1B 4/4885 |
| US-20070117839-A1 | Two cyclic cinnamide compound | APP, BACE1, PSEN1 | PSEN1 3/4885PSEN2 6/4885APH1B 11/4885 |
| US-20070219181-A1 | Multi-cyclic cinnamide derivatives | BACE1, APP, PSEN1 | PSEN1 3/4885PSEN2 6/4885APH1B 13/4885 |
| US-12043653-B2 | Efficient delivery of therapeutic molecules to cells of the inner ear | HES1, NOTCH1, NOTCH2 | PSEN1 1051/4885PSEN2 2053/4885APH1B 434/4885 |
| US-20070190046-A1 | Anti-abeta antibody | APP, APBA1, FCGR2A | PSEN1 6/4885PSEN2 9/4885APH1B 17/4885 |
| US-20080045499-A1 | Preferential Inhibition of Presenilin-1 | PSEN1, PSEN2, BACE1 | PSEN1 1/4885PSEN2 2/4885APH1B 8/4885 |
| US-20060004013-A1 | Alzheimer's disease, senile dementia, Down syndrome or amyloidosis; 3E)-1-[(1S)-1-(4-fluorophenyl)ethyl]-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]piperidin-2-one; imidazolyl-functional compounds inhibit production of Amyloid beta 40 and Amyloid beta 42; low hygroscopicity; good solubility | PSEN1, APP, BACE1 | PSEN1 1/4885PSEN2 4/4885APH1B 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.